Market Trends of Global Continuous Bioprocessing Industry
This section covers the major market trends shaping the Continuous Bioprocessing Market according to our research experts:
Research and Development Segment is Expected to Account for the Largest Market Share During the Forecast Period
The research and development segment is expected to grow significantly during the study period due to the increasing research and development expenditure, rising demand for biopharmaceuticals, the establishment of new facilities, and technological advancements in the segment.
For instance, in March 2021, Transcenta announced a breakthrough in its continuous perfusion cell culture platform by achieving volumetric productivity of over 6 g/L per day while maintaining process and product quality attributes in a state of control for a 4-week culture. This productivity improvement represents a 15-fold increase in drug substance output per year as compared to the same cell line in the conventional fed-batch process. This can increase the productivity of single-use bioreactors by approximately 130 kg or 1.3 metric tons of total drug substance per year. Thus, such advancements and increasing productivity through continuous bioprocessing will lead to lucrative growth of the market.
Furthermore, in March 2021, The United States Pharmacopeia (USP) and Phlow Corp. collaborated to build a new laboratory that will develop test methods and standards for continuous manufacturing. This establishment is focused on product development, tech transfer, and drug application filings using continuous manufacturing to foster wider adoption of continuous manufacturing by generic drugs and other pharmaceutical manufacturers. Moreover, the establishment of continuous biomanufacturing facilities which are focused on research and development activities will also contribute to the market growth. Thus, due to the above-mentioned factors, the studied segment is expected to contribute to the significant growth of the market.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
The primary driving factors for the growth of the North American continuous processing markets are the increasing burden of chronic diseases, product launches, key strategic initiatives by market players, the establishment of continuous bioprocessing facilities, and technological advancement in the studied market.
The United States within North America is expected to hold a significant share of the studied market during the study period. For instance, according to the estimates of the 2022 American Cancer Society, Inc., about 236,740 new cases of lung cancer will be diagnosed in the country in 2022. The same source also states that 79,000 new cases of kidney cancer and 13,920 deaths will be reported in 2022 from Kidney cancer. The high burden of cancer is expected to boost the demand for biosimilar and other biopharmaceuticals, thus driving the continuous bioprocessing market.
In March 2022, Phlow Corp., a U.S.-based essential medicines public benefit company, entered into strategic alliances with both Virginia Commonwealth University's (VCU) Medicines for All Institute and AMPAC Fine Chemicals to provide contract continuous manufacturing research and development (R&D) services for small molecule pharmaceutical products. Such partnerships will ramp up the operation of continuous manufacturing facilities, thus, driving the market.
The study 'A Comparative Investment Analysis of Batch Versus Continuous Pharmaceutical Manufacturing Technologies,' published in January 2022, suggested that continuous manufacturing has the potential to make manufacturing of oral solid dosage pharmaceuticals more economically attractive in the country than foreign manufacturing of those products. Thus, studies indicating the economic benefits in the US will boost the continuous manufacturing process in the country, which will significantly contribute to the market growth. Therefore, due to the above-mentioned factors, the studied market is expected to lead to lucrative growth in the market.
